A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial

Samankaltaisia teoksia

• A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
  Tekijä: Burnett, A, et al.
  Julkaistu: (2016)
• The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial
  Tekijä: Burnett, AK, et al.
  Julkaistu: (2018)
• Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
  Tekijä: Burnett, A, et al.
  Julkaistu: (2016)
• Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
  Tekijä: Freeman, SD, et al.
  Julkaistu: (2023)
• Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
  Tekijä: Hills, R, et al.
  Julkaistu: (2018)